Isentress - 2007 FDA approvals

Drug: Isentress (raltegravir potassium)
Indication: HIV
Company: Merck
Approval Date: October 12, 2007

Scoop: Isentress is the first agent in the class of antiretroviral agents known as integrase inhibitors. The drug is designed to slow the advancement of HIV-1 infection by blocking the HIV integrase enzyme that the virus needs in order to multiply. The drug is forecasted to reach $900 million in sales by 2012.

More news:
FDA approves Isentress. Report
FDA panel endorses Merck's new AIDS drug. Report

Isentress - 2007 FDA approvals

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.